An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Hims and Hers, the telehealth and wellness company, has started selling a generic form of semaglutide in Canada after the original maker, Novo Nordisk, lost patent protection there. In plain terms: a company is now offering a cheaper version of a popular weight-loss and diabetes drug in Canada because the exclusive rights that kept competitors out have expired. Semaglutide is the active ingredient behind brand-name drugs like Ozempic and Wegovy. It’s a man-made version of a hormone your gut makes that helps control appetite and blood sugar. It tells your brain “you’re full” more often, and it slows how quickly your stomach empties. Doctors use it for type 2 diabetes and, at higher doses, for weight loss. The news here is not a new medical study; it’s a market event. Hims is launching its own semaglutide product now that the Canadian patent has lapsed, meaning other companies can legally make and sell the same molecule there. This is about availability and price competition rather than new evidence about how the drug works. The snippet doesn’t say how Hims’ version compares in trials or what price it will be, and it doesn’t describe any safety testing beyond what regulators require for generics. Why this matters is straightforward. Generic versions usually cost less than brand-name drugs, so more people may be able to afford semaglutide in Canada. That could increase access for people with type 2 diabetes or those prescribed the drug for weight management. It may also ease shortages if demand had been outstripping supply. Investors and patients both watch these moves because they affect cost, availability, and which companies lead the market. Caveats are important. A generic should contain the same active drug, but formulations, dosing pens, and support services may differ from the brand. The snippet doesn’t say if Health Canada required specific studies for this product or if Hims offers medical oversight with prescriptions. Semaglutide has known side effects—nausea, diarrhea, and in rare cases more serious issues—and it requires medical judgment to use safely. Also, this change applies to Canada because of the patent status there; it may not reflect what’s possible in other countries where patents still hold. Bottom line: Hims is introducing a potentially cheaper semaglutide option in Canada thanks to a patent lapse, which could improve access but doesn’t change what we know about the drug’s effects or risks.
Source: foreignpolicyjournal.com